174 related articles for article (PubMed ID: 11592771)
1. Insulin-like growth factor-I and prostate cancer: a meta-analysis.
Shi R; Berkel HJ; Yu H
Br J Cancer; 2001 Sep; 85(7):991-6. PubMed ID: 11592771
[TBL] [Abstract][Full Text] [Related]
2. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
3. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States).
Li L; Yu H; Schumacher F; Casey G; Witte JS
Cancer Causes Control; 2003 Oct; 14(8):721-6. PubMed ID: 14674736
[TBL] [Abstract][Full Text] [Related]
4. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
[TBL] [Abstract][Full Text] [Related]
5. IGF-I and breast cancer: a meta-analysis.
Shi R; Yu H; McLarty J; Glass J
Int J Cancer; 2004 Sep; 111(3):418-23. PubMed ID: 15221971
[TBL] [Abstract][Full Text] [Related]
6. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
[TBL] [Abstract][Full Text] [Related]
8. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer.
Friedrichsen DM; Hawley S; Shu J; Humphrey M; Sabacan L; Iwasaki L; Etzioni R; Ostrander EA; Stanford JL
Prostate; 2005 Sep; 65(1):44-51. PubMed ID: 15800934
[TBL] [Abstract][Full Text] [Related]
9. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.
Miles FL; Goodman PJ; Tangen C; Torkko KC; Schenk JM; Song X; Pollak M; Thompson IM; Neuhouser ML
Nutrients; 2017 Apr; 9(4):. PubMed ID: 28417914
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.
Wolk A; Mantzoros CS; Andersson SO; Bergström R; Signorello LB; Lagiou P; Adami HO; Trichopoulos D
J Natl Cancer Inst; 1998 Jun; 90(12):911-5. PubMed ID: 9637140
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E
J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101
[TBL] [Abstract][Full Text] [Related]
12. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
[TBL] [Abstract][Full Text] [Related]
13. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
[TBL] [Abstract][Full Text] [Related]
15. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.
Mikami K; Ozasa K; Nakao M; Miki T; Hayashi K; Watanabe Y; Mori M; Sakauchi F; Washio M; Kubo T; Suzuki K; Wakai K; Nakachi K; Tajima K; Ito Y; Inaba Y; Tamakoshi A;
Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():57-61. PubMed ID: 20553083
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
[TBL] [Abstract][Full Text] [Related]
18. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.
Renehan AG; Zwahlen M; Minder C; O'Dwyer ST; Shalet SM; Egger M
Lancet; 2004 Apr; 363(9418):1346-53. PubMed ID: 15110491
[TBL] [Abstract][Full Text] [Related]
20. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
